

Ilayaraja Muthuramu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8880743/publications.pdf>

Version: 2024-02-01

27
papers

510
citations

567144

15
h-index

677027

22
g-index

27
all docs

27
docs citations

27
times ranked

854
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial effects of selective HDL-raising gene transfer on survival, cardiac remodelling and cardiac function after myocardial infarction in mice. <i>Gene Therapy</i> , 2013, 20, 1053-1061.	2.3	35
2	Protein Tyrosine Phosphatase SHP2 Mediates Chronic Insulin-Induced Endothelial Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1943-1950.	1.1	34
3	The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives. <i>Pharmaceuticals</i> , 2012, 5, 1372-1392.	1.7	33
4	Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. <i>Journal of Molecular Medicine</i> , 2015, 93, 609-618.	1.7	33
5	Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	29
6	Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1273.	1.8	29
7	Selective HDL-Raising Human Apo A-I Gene Therapy Counteracts Cardiac Hypertrophy, Reduces Myocardial Fibrosis, and Improves Cardiac Function in Mice with Chronic Pressure Overload. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2012.	1.8	27
8	The Impact of Lipoproteins on Wound Healing: Topical HDL Therapy Corrects Delayed Wound Healing in Apolipoprotein E Deficient Mice. <i>Pharmaceuticals</i> , 2014, 7, 419-432.	1.7	26
9	Lipid Lowering and HDL Raising Gene Transfer Increase Endothelial Progenitor Cells, Enhance Myocardial Vascularity, and Improve Diastolic Function. <i>PLoS ONE</i> , 2012, 7, e46849.	1.1	25
10	Successful treatment of established heart failure in mice with recombinant HDL (Milano). <i>British Journal of Pharmacology</i> , 2018, 175, 4167-4182.	2.7	25
11	Hepatocyte-Specific SR-BI Gene Transfer Corrects Cardiac Dysfunction in Scarb1 -Deficient Mice and Improves Pressure Overload-Induced Cardiomyopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2028-2040.	1.1	24
12	Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions. <i>Current Molecular Medicine</i> , 2014, 14, 481-503.	0.6	23
13	Coconut Oil Aggravates Pressure Overload-Induced Cardiomyopathy without Inducing Obesity, Systemic Insulin Resistance, or Cardiac Steatosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1565.	1.8	22
14	Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice. <i>Journal of Inflammation</i> , 2016, 13, 25.	1.5	21
15	Reconstituted HDL (Milano) Treatment Efficaciously Reverses Heart Failure with Preserved Ejection Fraction in Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3399.	1.8	20
16	Chick Embryo Partial Ischemia Model: A New Approach to Study Ischemia Ex Vivo. <i>PLoS ONE</i> , 2010, 5, e10524.	1.1	14
17	Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice. <i>Molecular Therapy</i> , 2017, 25, 2513-2525.	3.7	13
18	Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. <i>Scientific Reports</i> , 2020, 10, 8382.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Correction of endothelial dysfunction after selective homocysteine lowering gene therapy reduces arterial thrombogenicity but has no effect on atherogenesis. <i>Journal of Molecular Medicine</i> , 2011, 89, 1051-1058.	1.7	11
20	Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia. <i>Aging</i> , 2019, 11, 6872-6891.	1.4	11
21	HDL dysfunction, function, and heart failure. <i>Aging</i> , 2019, 11, 293-294.	1.4	10
22	New perspectives on biological HDL-targeted therapies. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 793-796.	1.4	8
23	Cholesterol-Lowering Gene Therapy Prevents Heart Failure with Preserved Ejection Fraction in Obese Type 2 Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2222.	1.8	8
24	Selective Homocysteine Lowering Gene Transfer Improves Infarct Healing, Attenuates Remodelling, and Enhances Diastolic Function after Myocardial Infarction in Mice. <i>PLoS ONE</i> , 2013, 8, e63710.	1.1	8
25	Role of lipids and lipoproteins in myocardial biology and in the development of heart failure. <i>Clinical Lipidology</i> , 2015, 10, 329-342.	0.4	7
26	Mesangial matrix expansion in a novel mouse model of diabetic kidney disease associated with the metabolic syndrome. <i>Journal of Nephropathology</i> , 2021, 10, e17-e17.	0.1	1
27	Increased Remnant Lipoproteins in Apo E Deficient Mice Induce Coronary Atherosclerosis following Transverse Aortic Constriction and Aggravate the Development of Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure. <i>Biomedicines</i> , 2022, 10, 1592.	1.4	0